With the multiple myeloma drug’s climb from fifth- to second-line therapy, Carvykti uptake is set to expand. Legend Biotech CEO Ying Huang discusses timing of a crucial supply bump.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,